Key result
Novel biosensor assay detects troponin structural changes with ~9% lifetime shift to enable high-throughput screening.
Why the study?
Targeting sarcomeric contractile proteins is a promising therapy for heart failure, but developing novel interventions has been challenging due to a lack of precise discovery tools.
Does a fluorescence lifetime-based assay using human IANBD-cTnCT53C exchanged into porcine cardiac myofibrils provide sufficient precision and sensitivity (Z' factor) to detect thin and thick filament activation states for high-throughput drug screening?
Does a fluorescence lifetime-based assay using human IANBD-cTnCT53C exchanged into porcine cardiac myofibrils provide sufficient precision and sensitivity (Z' factor) to detect thin and thick filament activation states for high-throughput drug screening?
Answers are grounded in this paper and cite their sources.
This preclinical study establishes a high-precision fluorescence lifetime plate-reader assay in intact cardiac myofibrils capable of high-throughput screening for novel small-molecule modulators of sarcomeric thin and thick filament regulation.
Cardiac muscle contraction is regulated by Ca2+-induced structural changes of the thin filaments to permit myosin cross-bridge cycling driven by ATP hydrolysis in the sarcomere. In congestive heart failure, contraction is weakened, and thus targeting the contractile proteins of the sarcomere is a promising approach to therapy. However, development of novel therapeutic interventions has been challenging due to a lack of precise discovery tools. We have developed a fluorescence lifetime-based assay using an existing site-directed probe, N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine (IANBD) attached to human cardiac troponin C (cTnC) mutant cTnCT53C, exchanged into porcine cardiac myofibrils. We hypothesized that IANBD-cTnCT53C fluorescence lifetime measurements provide insight into the activation state of the thin filament. The sensitivity and precision of detecting structural changes in cTnC due to physiological and therapeutic modulators of thick and thin filament functions were determined. The effects of Ca2+ binding to cTnC and myosin binding to the thin filament were readily detected by this assay in mock high-throughput screen tests using a fluorescence lifetime plate reader. We then evaluated known effectors of altered cTnC-Ca2+ binding, W7 and pimobendan, and myosin-binding drugs, mavacamten and omecamtiv mecarbil, used to treat cardiac diseases. Screening assays were determined to be of high quality as indicated by the Z' factor. We conclude that cTnC lifetime-based probes allow for precise evaluation of the thin filament activation in functioning myofibrils that can be used in future high-throughput screens of small-molecule modulators of function of the thin and thick filaments.
No takes yet. Share an insight, caveat, or question.
Dvornikov et al. (2022) studied Cardiac muscle contractile regulation (in vitro porcine ventricular myofibrils) (n=4). IANBD-cTnCT53C time-resolved fluorescence lifetime assay with Ca2+, ATP, W7, pimobendan, mavacamten, and omecamtiv mecarbil vs. Low Ca2+ (pCa 9), rigor condition, or 1% DMSO vehicle control was evaluated on Fluorescence lifetime (ns) of IANBD-cTnCT53C in rigor conditions at high Ca2+ (pCa 4.5) vs low Ca2+ (pCa 9) across 4 experiments (p=7.7 × 10^-24). IANBD-cTnCT53C fluorescence lifetime decreased by an average of 9.4% upon Ca2+ binding in porcine myofibrils with an average Z' factor of 0.67, enabling high-throughput screening.
Synapse has enriched 10 related papers. Consider them for comparative context: